SAB Biotherapeutics (SABS) EBT (2021 - 2026)
SAB Biotherapeutics (SABS) reported EBT of -$19.0 million for Q1 2026, down 76.39% on a YoY basis from -$80.5 million in Q1 2025, and down 25.64% quarter-over-quarter from -$15.1 million in Q4 2025.
SAB Biotherapeutics (SABS) EBT (2021 - 2026) Analysis & Trends
SAB Biotherapeutics has reported EBT for 6 years, with the latest figure at -$19.0 million in Q1 2026.
- For the quarter ending Q1 2026, EBT fell 76.39% year-over-year to -$19.0 million; the trailing twelve-month figure through Mar 2026 stood at -$56.0 million (down 45.8% YoY), and the FY2025 full-year result was -$47.8 million, down 13.87% from the prior year.
- EBT for Q1 2026 stood at -$19.0 million, down from -$15.1 million in the prior quarter.
- The five-year high for EBT was $1.1 million in Q1 2022, with the low at -$22.9 million in Q4 2023.
- Historically, EBT has averaged -$9.4 million across 5 years, with a median of -$7.8 million in 2022.
- Annual changes were most pronounced in 2023 — EBT sank 782.08% — and 2024, when it jumped 56.5%.
- SAB Biotherapeutics' EBT stood at -$7.8 million in 2022, then slumped by 191.21% to -$22.9 million in 2023, then surged by 56.5% to -$9.9 million in 2024, then slumped by 52.19% to -$15.1 million in 2025, then slipped by 25.64% to -$19.0 million in 2026.
- The last three EBT figures came in at -$19.0 million (Q1 2026), -$15.1 million (Q4 2025), and -$12.1 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | -26.94 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -2.97 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 19.60 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | -3.18 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -15.31 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | -1.50 Mn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.25 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -56.48 Mn |
| 10 | SAB Biotherapeutics | 214.77 Mn | 214.77 Mn | - | -19.01 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -19.01 Mn |
| Dec 31, 2025 | -15.13 Mn |
| Sep 30, 2025 | -12.07 Mn |
| Jun 30, 2025 | -9.78 Mn |
| Mar 31, 2025 | -10.78 Mn |
| Dec 31, 2024 | -9.94 Mn |
| Sep 30, 2024 | -10.35 Mn |
| Jun 30, 2024 | -7.34 Mn |
| Mar 31, 2024 | -5.03 Mn |
| Dec 31, 2023 | -22.86 Mn |
| Sep 30, 2023 | -5.10 Mn |
| Jun 30, 2023 | -6.88 Mn |
| Mar 31, 2023 | -7.35 Mn |
| Dec 31, 2022 | -7.85 Mn |
| Sep 30, 2022 | -7.08 Mn |
| Jun 30, 2022 | -4.87 Mn |
| Mar 31, 2022 | 1.08 Mn |
| Dec 31, 2021 | -11.55 Mn |
| Sep 30, 2021 | -4.06 Mn |
| Jun 30, 2021 | -2.94 Mn |